The bioflavonoid galangin suppresses the growth of ehrlich ascites carcinoma in Swiss Albino Mice: A molecular insight

Applied Biochemistry and Biotechnology

Volumn 167, Issue 5, 2012, Pages 1325-1339

  Jaiswal, Jai V ^a   Wadegaonkar, Prasad A ^a   Hajare, Sunil W ^b  

^a SANT GADGE BABA AMRAVATI UNIVERSITY   (India)

^b PG Institute of Veterinary Sciences   (India)

Author keywords

ADMET; Animal model; Apoptosis; Bioflavonoid; Docking; Erhlich ascites carcinoma; Galangin

Indexed keywords

ADMET; ANIMAL MODEL; BIOFLAVONOID; ERHLICH ASCITES CARCINOMA; GALANGIN;

BINDING ENERGY; CELL DEATH; DOCKING; LEAD COMPOUNDS; MAMMALS; PLANTS (BOTANY); PROTEINS;

DISEASES;

APOPTOSIS INHIBITOR IAP HOMOLOG; APOPTOSIS INHIBITOR SURVIVIN; B RAF KINASE; BRCA1 PROTEIN; CAMPTOTHECIN; CRK ASSOCIATED SUBSTRATE PROTEIN; CURCUMIN; DACTINOMYCIN; ENZYME PRECURSOR; ETOPOSIDE; FLUOROURACIL; GALANGIN; INHIBITOR OF APOPTOSIS PROTEIN XIAP; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD BRAIN BARRIER; CANCER CONTROL; CANCER INHIBITION; CANCER MORTALITY; CARCINOGENESIS; CARCINOGENICITY; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; COMPUTER MODEL; CONFERENCE PAPER; CONTROLLED STUDY; CYTOPLASM; DNA FRAGMENTATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; EHRLICH ASCITES TUMOR; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PERITONEAL CAVITY; PHARMACOKINETICS; RAT; SKIN PERMEABILITY; TREATMENT OUTCOME; TUMOR GROWTH;

ABSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA FRAGMENTATION; FLAVONOIDS; HUMANS; MALE; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ALPINIA GALANGA; ANIMALIA; MUS;

EID: 84866402554     PISSN: 02732289     EISSN: 15590291     Source Type: Journal    
DOI: 10.1007/s12010-012-9646-3     Document Type: Conference Paper

References (64)

1. Rethinking cancer. (2010). Available from http://physics.cancer.gov/ global/docs/PWJun10davies.pdf 25 February 2012
2. American Cancer Society, A biotechnology company dedicated to cancer treatment. (2006). Available from: www.cancervax.com/info/index.htm.25 January 2006
3. Somkumar, A. P. (2003). Studies on anticancer effects of Ocimum sanctum and Withania somnifera on experimentally induced cancer in mice. Ph D thesis, J. N. K. V. University, Jabalpur, India.
4. Pandey, G.,&Madhuri, S. (2006). Medicinal plants: Better remedy for neoplasm. Indian Drugs, 43, 869-874.
5. Cseke, L. J., Kaufman, P. B., Podila, G. K., & Tsai, C. J. (2004). Molecular and cellular methods in biology and medicine (2nd ed.). Boca Raton: CRC Press.
6. Block, G., Patterson, B., & Subar, A. (1992). Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence. Nutrition and Cancer, 18, 1-29.
7. Messina, M., Descheemaker, K., & Erdman, J. W., Jr. (1998). The role of soy in preventing and treating chronic disease. American Journal of Clinical Nutrition, 68, 1329S (Proceedings of the Second International Symposium on the Role of Soy in Preventing and Treating Chronic Disease held on September 15-18, 1996, and a satellite symposium held on September 19, 1996, in Brussels, Belgium-Preface).
8. Steinmetz, K. A., & Potter, J. D. (1991). Vegetables, fruit, and cancer. I. Epidemiology. Cancer Causes & Control, 2, 325-357.
9. Wattenberg, L. W. (1992). Inhibition of carcinogenesis by minor dietary constituents. Cancer Research, 52(suppl), 2085s-2091s.
10. Wattenberg, L.W. (1992). Chemoprevention of cancer by naturally occurring and synthetic compounds. In L. W.Wattenberg,M. Lipkin, C.W. Kelloff, & G. J. Kelloff (Eds.), Cancer chemoprevention (pp. 19-39). Boca Raton: CRC Press.
11. Waladkhani, A. R., & Clemens, M. R. (1998). Effect of dietary phytochemicals on cancer development. International Journal of Medical, 1, 747-753.
12. Steinmetz, K. A., & Potter, J. D. (1991). Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes & Control, 2, 427-442.
13. Adlercreutz, H. (1990). Western diet and Western diseases: Some hormonal and biochemical mechanisms and associations. Scandinavian Journal of Clinical & Laboratory Investigation, 50(Suppl. 201), 3-23.
14. Havsteen, B. (1983). Flavonoids, a class of natural products of high pharmacological potency. Biochemical Pharmacology, 32, 1141-1148.
15. Middleton, E., Jr., & Chithan, K. (1993). The impact of plant flavonoids on mammalian biology: Implications for immunity, inflammation and cancer. In J. B. Harborne (Ed.), The flavonoids: Advances in research since 1986. London: Chapman and Hall.
16. Grange, J. M., & Davey, R. W. (1990). Antibacterial properties of propolis (bee glue). Journal of the Royal Society of Medicine, 83, 159-160.
17. Harborne, J. B., & Baxter, H. (1999). The handbook of natural flavonoids, vols 1 and 2. Chichester: Wiley.
18. Scalbert, A., & Williamson, G. (2000). Dietary intake and bioavailability of dietary polyphenols. Journal of Nutrition, 130, 2073S-2085S.
19. Vaouzour, D., Vafeiadou, K., Rodriguez-Mateos, A., Rendeiro, C., & Spencer, J. P. (2008). The neuroprotective potential of flavonoids: A multiplicity of effects. Genetics Nutrition, 3, 115-126.
20. Rathee, P., Chaudhary, H., Rathee, S., Rathee, D., Kumar, V., & Kohli, K. (2009). Mechanism of action of flavonoids as anti-inflammatory agents: A review. Inflammation & Allergy Drug Targets, 8, 229-235.
21. Andres, A., Donovan, S. M., & Kuhlenschmidt, M. S. (2009). Soy isoflavones and virus infections. The Journal of Nutritional Biochemistry, 20, 563-569.
22. Li, B. H., & Tian, W. X. (2003). Presence of fatty acid synthase inhibitors in the rhizome of Alpinia officinarum hance. Journal of Enzyme Inhibition and Medicinal Chemistry, 18, 349-356.
23. Volpi, N. (2004). Separation of flavonoids and phenolic acids from propolis by capillary zone electrophoresis. Electrophoresis, 25, 1872-1878.
24. Borrelli, F., Maffia, P., Pinto, L., Ianaro, A., Russo, A., Capasso, F., & Ialenti, A. (2002). Phytochemical compounds involved in the anti-inflammatory effect of propolis extract. Fitoterapia, 73(Suppl 1), S53-S63.
25. So, F. V., Guthrie, N., Chambers, A. F., & Carroll, K. K. (1997). Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Letters, 112, 127-133.
26. Wall, M. E., Wani, M. C., Manikumar, G., Abraham, P., Taylor, H., Hughes, T. J., Warner, J., & McGivney, R. (1988). Plant antimutagenic agents: Flavonoids. Journal of Natural Products, 51(6), 1084-1091.
27. Cholbi, M. R., Paya, M., & Alcaraz, M. J. (1991). Inhibitory effects of phenolic compounds on CCl4-induced microsomal lipid peroxidation. Experientia, 47(2), 195-199.
28. Imamura, Y., Migita, T., Uriu, Y., Otagiri, M., & Okawara, T. (2000). Inhibitory effects of flavonoids on rabbit heart carbonyl reductase. Journal of Biochemistry, 127(4), 653-658.
29. Capasso, R., & Tavares, I. A. (2002). Effect of the flavonoid galangin on urinary bladder rat contractility in vitro. Journal of Pharmacy and Pharmacology, 54(8), 1147-1150.
30. Heo, M. Y., Yu, K. S., Kim, K. H., Kim, H. P., & Au, W. W. (1992). Anti-clastogenic effect of flavonoids against mutagen-induced micronuclei in mice. Mutation Research, 284(2), 243-249.
31. Heo, M. Y., Lee, S. J., Kwon, C. H., Kim, S.W., Sohn, D. H., & Au,W.W. (1994). Anticlastogenic effects of galangin against bleomycin-induced chromosomal aberration in mouse spleen lymphocytes. Mutation Research, 311(2), 225-229.
32. Gabor, M., & Razga, Z. (1991). Effect of benzopyrone derivatives on simultaneously induced croton oil ear oedema and carrageenin paw oedema in rats. Acta Physiologica Hungarica, 77(3-4), 197-207.
33. Kang, S. S., Kim, J. S., Son, K. M., Kim, H. P., & Chang, H. W. (2000). Isolation of COX-2 inhibitors from Alpinia officinarum. Korean Journal of Pharmacognosy, 31, 57-62.
34. Shih, H., Pickwell, G. V., & Quattrochi, L. C. (2000). Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer. Archives of Biochemistry and Biophysics, 373(1), 287-294.
35. Buening, M. K., Chang, R. L., Huang, M. T., Fortner, J. G., Wood, A. W., & Conney, A. H. (1981). Activation and inhibition of benzo[a]pyrene and aflotoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Research, 41(1), 67-72.
36. Ciolino, H. P., & Yeh, G. C. (1999). The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the arly hydrocarbon receptor. British Journal of Cancer, 79(9-10), 1340-1346.
37. Sohn, S. J., Huh, I. H., Au, W. W., & Heo, M. Y. (1998). Antigenotoxicity of galangin against N-methyl-N-nitrosourea. Mutation Research, 402(1-2), 231-236.
38. Hansen, M. B., Nielsen, S. E., & Berg, K. (1989). Re-examination and further development of a precise and rapid dye methods for measuring cell growth/cell kill. Journal of Immunological Methods, 119, 203-210.
39. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., et al. (1998). Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. Journal of Computational Chemistry, 19, 1639-1662.
40. Ahmed, H., Chatterjee, B. P., & Debnath, A. K. (1988). Interaction and in vivo growth inhibition of Ehrlich ascites tumor cells by jacalin. Journal of Biosciences, 13(4), 419-424.
41. Murray, T. J., Yang, X., & Sherr, D. H. (2006). Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A. Breast Cancer Research, 8(2), 2-13.
42. Brown, D. G., Sun, X.M.,&Cohen, G.M. (1993).Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. Journal of Biological Chemistry, 268, 3037-3039.
43. Oberhammer, F., Wilson, J. W., Dive, C., Morris, I. D., Hickman, J. A., Wakeling, A. E., Walker, P. R., & Sikorska, M. (1993). Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO Journal, 12, 3679-3684.
44. Walker, P. R., Smith, C., Youdale, T., Leblanc, J., Whitfield, J. F., & Sikorska, M. (1991). Topoisomerase II reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Research, 51, 1078-1085.
45. Granville, D. J., Carthy, C. M., Hunt, D. W., & McManus, B. M. (1998). Apoptosis: Molecular aspects of cell death and disease. Laboratory Investigation, 78, 893-913.
46. Nagata, S. (2000). Apoptotic DNA fragmentation. Experimental Cell Research, 256, 12-18.
47. Nicholson, D. W., & Thornberry, N. A. (1997). Caspases: Killer proteases. Trends in Biochemical Sciences, 22, 299-306.
48. Tao, H., Luo, H., Wu, J., Lan, L-bo, Fan, D-hua, Zhu, K-dan, Chen, X-yi, et al. (2010). Galangin induces apoptosis of hepatocellular carcinoma cells via the mitochondrial pathway. Apoptosis, 16(27), 3377-3384.
49. Heo, M. Y., Sohn, S. J., & Au, W. W. (2001). Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate. Mutation Research: Reviews in Mutation Research, 488, 135-150.
50. Monasterio, A., Urdaci, M. C., Pinchuk, I. V., Lopez-Moratalla, N., & Martinez-Irujo, J. J. (2004). Flavonoids induce apoptosis in human leukemia U937 cells through caspase-and caspase-calpaindependent pathways. Nutrition and Cancer, 50, 90-100.
51. Kennedy, T. (1997).Managing the drug discovery/development interface.DrugDiscovery Today, 2, 436-444.
52. Clark, D. E., & Grootenhuis, P. D. (2002). Progress in computational methods for the prediction of ADMET properties. Current Opinion in Drug Discovery & Development, 5, 382-390.
53. Modi, S. (2003). Computational approaches to the understanding of ADMET properties and problems. Drug Discovery Today, 8, 621-623.
54. Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: Towards prediction paradise? Nature Reviews Drug Discovery, 2, 192-204.
55. Artursson, P., & Karlsson, J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications, 175, 880-885.
56. Artursson, P., & Borchardt, R. T. (1997). Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharmaceutical Research, 14, 1655-1658.
57. Lipin-ski, C. A., Lombardo, F., Dominy, B. W., & Feeny, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23, 3-25.
58. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery, 3, 711-716.
59. Kararli, T. T. (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharmaceutics & Drug Disposition, 16, 351-380.
60. Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96, 736-749.
61. Artursson, P. (1990). Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. Journal of Pharmaceutical Sciences, 79, 476-482.
62. Irvine, J. D., Takahashi, L. K., Lockhart, J., Cheong, J. W., Tolan, H. E., Selick, J., & Grove, R. (1999). MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. Journal of Pharmaceutical Sciences, 88, 28-33.
63. Jelic, D., Rusak, G., Domac, J., Goran, S., Kovarik, Z., & Antolovic, R. (2010). Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase. European Journal of Medicinal Chemistry, 45, 186-192.
64. Gupta, M., Upal, K., Haldar, P. K., & Kandar, C. C. (2007). Anticancer activity of Indigofera aspalathoides and Wedelia calendulaceae in Swiss Albino mice. Iranian Journal of Pharmaceutical Research, 6 (2), 141-145.